Noh Ji-Won, Yoo Jung-Hwa, Lee Byung-Cheol
Department of Clinical Korean Medicine, College of Korean Medicine, Graduate School, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.
Pharmaceuticals (Basel). 2024 Aug 27;17(9):1131. doi: 10.3390/ph17091131.
Rising obesity and associated multi-systemic complications amplify the health burden. Euphorbia kansui (EK) extract is clinically recognized for managing obesity. In a human study, 240 obese individuals were categorized into two cohorts: those receiving solely herbal medicine (HM group) and those administered EK concomitantly with herbal medicine (EK group). An in vivo examination using C57BL/6-/ mice elucidated mechanisms involving macrophages and gut microbiota with associated metabolic advantages. The clinical study revealed a significant 7.22% body weight reduction during 91.55 average treatment days and examined 16.71% weight loss at 300 days after treatment. In whole subjects, 60.4%, 21.3%, and 6.3% achieved weight reductions exceeding 5%, 10%, and 15%, respectively. Impressively, the EK group exhibited superior weight loss compared to the HM group (EK: -7.73% vs. HM: -6.27%, = 0.012). The anti-obesity effect was positively associated with EK therapy frequency and herbal medicine duration. In the in vivo study, EK significantly improved insulin sensitivity and mitigated infiltration of adipose tissue macrophages (ATMs) by modulating the CD11c+ and CD206+ subtypes. EK also correlated with increased and populations and reduced and . Consequently, EK is an effective adjunctive anti-obesity therapy offering metabolic benefits by modulating ATMs and gut microbiota profiles.
肥胖率上升及相关的多系统并发症加重了健康负担。甘遂提取物在临床上被认可用于治疗肥胖症。在一项人体研究中，240名肥胖个体被分为两组：仅接受草药治疗的组（草药组）和同时接受甘遂与草药治疗的组（甘遂组）。一项使用C57BL/6 - /小鼠的体内研究阐明了涉及巨噬细胞和肠道微生物群的机制以及相关的代谢优势。临床研究显示，在平均91.55天的治疗期间体重显著减轻了7.22%，且在治疗后300天时体重减轻了16.71%。在所有受试者中，分别有60.4%、21.3%和6.3%的人体重减轻超过了5%、10%和15%。令人印象深刻的是，与草药组相比，甘遂组的体重减轻更为显著（甘遂组：-7.73% vs. 草药组：-6.27%，P = 0.
012）。抗肥胖效果与甘遂治疗频率和草药治疗持续时间呈正相关。在体内研究中
